Maridebart Cafraglutide

Phase 3Peptide

Maridebart Cafraglutide is one of 181 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Heart FailureActive, not recruiting

ObesityNot yet recruiting

Heart Failure With Preserved Ejection FractionRecruiting

Atherosclerotic Cardiovascular DiseaseRecruiting

Obesity or OverweightRecruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Obstructive Sleep ApneaPhase 3

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

ObesityPhase 3

Not yet recruiting

Heart Failure With Preserved Ejection FractionPhase 3

Recruiting

Atherosclerotic Cardiovascular DiseasePhase 3

Recruiting

Obesity or OverweightPhase 3

Recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

20 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

LCZ696

Novartis

Preclinical

15 7

Monoferric

PPharmacosmos A/S

Preclinical

5 8

Activase

Zemplar

Savaysa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Heart

NCT07229157

Q4 2026

Phase 2Active, not recruiting

Type 2 Diabetes Mellitus

NCT06660173

Phase 1Recruiting

Obesity

NCT07523711

Phase 1Recruiting

Type 2 Diabetes Mellitus

NCT07160257

Q2 2027

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06858839

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06858878

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

Recruiting· Amgen logo

Amgen·Phase 1·NCT07160257·70 enrolled

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06858839·3,853 enrolled

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Active, not recruiting· Amgen logo

Amgen·Phase 2·NCT06660173·409 enrolled

Show 2 more trials

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06858878·1,105 enrolled

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Completed· Amgen logo

Amgen·Phase 2·NCT05669599·592 enrolled

Obesity5 trials

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Completed· Amgen logo

Amgen·Phase 1·NCT04478708·110 enrolled

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06987695·279 enrolled

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight

Not yet recruiting· Amgen logo

Amgen·Phase 3·NCT07684235·3,200 enrolled

Show 2 more trials

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus

Not yet recruiting· Amgen logo

Amgen·Phase 3·NCT07684144·950 enrolled

A Phase 1, Open-label Study to Assess the Effect of Maridebart Cafraglutide (AMG 133) on the Pharmacokinetics of Oral Contraceptives in Postmenopausal Female Participants Living With Overweight or Obesity

Recruiting· Amgen logo

Amgen·Phase 1·NCT07523711·45 enrolled

Obstructive Sleep Apnea2 trials

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Recruiting· Amgen logo

Amgen·Phase 3·NCT07226765·250 enrolled

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Recruiting· Amgen logo

Amgen·Phase 3·NCT07225686·250 enrolled

Overweight2 trials

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Recruiting· Amgen logo

Amgen·Phase 2·NCT07441252·180 enrolled

A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

Completed· Amgen logo

Amgen·Phase 1·NCT06352892·20 enrolled

ART1 trial

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT07226778·348 enrolled

5 more indications

Trial1 trial

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT07313761·349 enrolled

Heart1 trial

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT07229157·81 enrolled

Atherosclerotic Cardiovascular Disease1 trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Recruiting· Amgen logo

Amgen·Phase 3·NCT07037433·12,800 enrolled

Obesity or Overweight1 trial

A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight

Recruiting· Amgen logo

Amgen·Phase 3·NCT07575399·300 enrolled

Heart Failure With Preserved Ejection Fraction1 trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Recruiting· Amgen logo

Amgen·Phase 3·NCT07037459·5,056 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Maridebart Cafraglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Maridebart Cafraglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Maridebart Cafraglutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Amgen

Maridebart Cafraglutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

Obesity5 trials

Obstructive Sleep Apnea2 trials

Overweight2 trials

ART1 trial

Trial1 trial

Heart1 trial

Atherosclerotic Cardiovascular Disease1 trial

Obesity or Overweight1 trial

Heart Failure With Preserved Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News